Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Launches Alcoholism Drug Campral Through Antidepressant Sales Reps

This article was originally published in The Pink Sheet Daily

Executive Summary

Lipha/Forest's alcoholism treatment Campral (acamprosate) will be available at an average wholesale price of about $4.36 per day

You may also be interested in...



Forest Ends Daiichi Azor Deal To Focus On Its Own Products

Japanese pharma gets $26 million break-up fee as co-promotion ends.

Forest Ends Daiichi Azor Deal To Focus On Its Own Products

Japanese pharma gets $26 million break-up fee as co-promotion ends.

Forest/Lipha Campral Approved On Re-Audit; FDA Backs Off Additional Study Request

Alcoholism agent Campral skirts additional trial requirement via re-audit of European data to address data handling concerns, FDA review documents show. Issues of concern include “sloppy” data collection and poorly defined primary endpoints. Re-working of data from three pivotal, non-U.S. studies overturns June 2002 “not approvable” finding.

Related Content

Topics

UsernamePublicRestriction

Register

MT142464

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel